Search research articles
Contact Us
Filters
Showing results (751-760 of 837) with videos related to
Page
of 84
Sort By:
Nature Chemical Biology
|
October 2, 2012
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Georg E Winter, Uwe Rix, Scott M Carlson, et al.
Medical Care
|
July 2, 2014
Effect of self-referral on bone mineral density testing and osteoporosis treatment
Amy H Warriner, Ryan C Outman, Adrianne C Feldstein, et al.
Neurodegenerative Disease Management
|
November 24, 2021
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design
Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2019
HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Fernanda Faião-Flores, Michael F Emmons, Michael A Durante, et al.
Journal of Medicinal Chemistry
|
September 25, 2007
Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators
Esther Martinborough, Yixing Shen, Arjan van Oeveren, et al.
The New Zealand Medical Journal
|
December 12, 2024
Process of development of decentralised clinical trial methodology for cancer clinical trials in Aotearoa New Zealand
Nicola J Lawrence, Bobbi B Laing, Joseph Tyro, et al.
Neurology
|
November 26, 2013
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology
Robert G Miller, Benjamin Rix Brooks, Rebecca J Swain-Eng, et al.
Journal of Medicinal Chemistry
|
October 12, 2010
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models
Joseph E Payne, Céline Bonnefous, Kent T Symons, et al.
Blood
|
June 18, 2011
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
Karoline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, et al.
Nature Genetics
|
March 11, 2008
Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome
Carmen C Leitch, Norann A Zaghloul, Erica E Davis, et al.
Page
of 84
Search research articles
Search
Showing results (751-760 of 837) with videos related to
Sort By:
Page
of 84
Nature Chemical Biology
|
October 2, 2012
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Georg E Winter, Uwe Rix, Scott M Carlson, et al.
Medical Care
|
July 2, 2014
Effect of self-referral on bone mineral density testing and osteoporosis treatment
Amy H Warriner, Ryan C Outman, Adrianne C Feldstein, et al.
Neurodegenerative Disease Management
|
November 24, 2021
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design
Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2019
HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Fernanda Faião-Flores, Michael F Emmons, Michael A Durante, et al.
Journal of Medicinal Chemistry
|
September 25, 2007
Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators
Esther Martinborough, Yixing Shen, Arjan van Oeveren, et al.
The New Zealand Medical Journal
|
December 12, 2024
Process of development of decentralised clinical trial methodology for cancer clinical trials in Aotearoa New Zealand
Nicola J Lawrence, Bobbi B Laing, Joseph Tyro, et al.
Neurology
|
November 26, 2013
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology
Robert G Miller, Benjamin Rix Brooks, Rebecca J Swain-Eng, et al.
Journal of Medicinal Chemistry
|
October 12, 2010
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models
Joseph E Payne, Céline Bonnefous, Kent T Symons, et al.
Blood
|
June 18, 2011
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
Karoline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, et al.
Nature Genetics
|
March 11, 2008
Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome
Carmen C Leitch, Norann A Zaghloul, Erica E Davis, et al.
Page
of 84